Inhibition of tumor cell kinetics and serum insulin growth factor I levels by octreotide in colorectal cancer patients

Cascinu, Stefano; Ferro, Elena Del; Grianti, Cesare; Ligi, M.; Ghiselli, Roberto; Foglietti, G; Saba, Vittorio; Lungarotti, F; Catalano, Giuseppina

doi:10.1016/s0016-5085(97)70170-7

Cited by 28 publications

(17 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Cascinu et al, however, in a follow-up study in 1997 (105), did measure IGF-I concentrations. They randomized 75 patients with newly diagnosed colon cancer to receive either octreotide, 200 g subcutaneously three times per day, or placebo for 2 weeks before surgery.…”

Section: Igf Effects On Tumor Growthmentioning

confidence: 99%

The Effects of Insulin-Like Growth Factors on Tumorigenesis and Neoplastic Growth

2000

View full text Add to dashboard Cite

Several decades of basic and clinical research have demonstrated that there is an association between the insulin-like growth factors (IGFs) and neoplasia. We begin with a brief discussion of the function and regulation of expression of the IGFs, their receptors and the IGF-binding proteins (IGFBPs). A number of investigational interventional strategies targeting the GH or IGFs are then reviewed. Finally, we have assembled the available scientific knowledge about this relationship for each of the major tumor types. The tumors have been grouped together by organ system and for each of the major tumors, various key elements of the relationship between IGFs and tumor growth are discussed. Specifically these include the presence or absence of autocrine IGF-I and IGF-II production; presence or absence of IGF-I and IGF-II receptor expression; the expression and functions of the IGFBPs; in vitro and in vivo experiments involving therapeutic interventions; and available results from clinical trials evaluating the effect of GH/IGF axis down-regulation in various malignancies. (Endocrine Reviews 21: 2000)

show abstract

Section: Igf Effects On Tumor Growthmentioning

confidence: 99%

The Effects of Insulin-Like Growth Factors on Tumorigenesis and Neoplastic Growth

2000

View full text Add to dashboard Cite

show abstract

“…However, octreotide, a synthetic somatostatin analog known to reduce circulating IGF-I levels, lowers proliferative activity of tumor cells in patients with colorectal cancer [54], reduces tumor growth in animal studies [51, 55]and may prolong survival modestly in patients with colorectal cancer refractory to chemotherapy [56]. The major impact of IGF-I and IGFBP-3 may occur earlier in the development of cancer, during the prediagnostic phases, as the increasing genetic instability and heterogeneity of advanced tumors frequently deflect attempts at treatment.…”

Section: Potential Implications Of the Association Between Igf And Vamentioning

confidence: 99%

Insulin-Like Growth Factor-I and Binding Protein-3 and Risk of Cancer

Giovannucci¹

1999

Horm Res Paediatr

152

View full text Add to dashboard Cite

Insulin-like growth factor (IGF)-I is an important mitogen required by some cell types to progress from the G1 phase to the S phase of the cell cycle. IGF binding proteins (IGFBPs) can have opposing actions, in part by binding IGF-I, but also by direct inhibitory effects on target cells. As mitogens and anti-apoptotic agents, IGFs may be important in carcinogenesis, possibly by increasing the risk of cellular transformation by enhancing cell turnover. Indeed, many types of neoplastic cells express or overexpress IGF-I receptors, which stimulate mitogenesis when activated by IGF-I in vitro. In vivo, tissue IGF bioactivity is determined not only by circulating IGF-I and IGFBP levels, but also by local production of IGFs, IGFBPs, and possibly IGFBP proteases that enhance IGF-I availability by cleaving IGFBPs. Because determinants of tissue IGF bioactivity appear to be regulated in parallel with circulating IGF-I level, it is reasonable to hypothesize that the substantial intraindividual variability in circulating levels of IGF-I and IGFBP-3 may be important in determining risk of some cancers. In recent epidemiologic studies, relatively high plasma IGF-I and low IGFBP-3 levels have been independently associated with greater risk of prostate cancer in men, breast cancer among premenopausal women, and colorectal adenoma and cancer in men and women and possibly lung cancer. These include prospective data from the Physicians’ Health Study and the Nurses’ Health Study. In general, two- to fourfold elevated risks have been observed for prostate cancer in men in the top quartile of IGF-I relative to those in the bottom quartile, and low levels of IGFBP-3 were associated with an approximate doubling of risk. For breast cancer, an association with IGF-I for postmenopausal women was not apparent, but strong associations were observed for premenopausal cases in the Nurses’ Health Study. Further study is needed to confirm this subgroup finding in women. Recent data also indicate that high IGF-I and low IGFBP-3 increase risk of colorectal cancer and large or villous adenomas. Of note, for colorectal neoplasia, fourfold elevated risks were observed in men and women with low IGFBP-3, whereas high IGF-I was associated with a doubling of risk. These emerging epidemiologic data indicate that high levels of IGF-I and low levels of IGFBP-3 are associated with an increased risk of at least several types of carcinoma that are common in economically developed countries. Further study is required to determine the clinical relevance of these findings.

show abstract

“…SS and its analogs inhibit in vivo and in vitro tumoral colon cell proliferation and metastatic development (4,5). However, patients with advanced colorectal cancer treated with SS analogs did not present significant benefits although their tumoral markers decreased (6,7).…”

Section: Introductionmentioning

confidence: 99%

No loss of sst receptors gene expression in advanced stages of colorectal cancer

Vuaroqueaux¹,

Dutour²,

Briard³

et al. 1999

European Journal of Endocrinology

View full text Add to dashboard Cite

As demonstrated by several studies, the pan-inhibitory peptide somatostatin (SS) is implicated in a large variety of physiological processes in the gastrointestinal tractus. SS inhibits hormonal and gastric acid secretions, and decreases gastric and intestinal motility, mesenteric blood flow and intestinal absorption. In vitro and in vivo studies showed also that the antiproliferative potency of SS analogs may be a target to improve the prognosis of colorectal cancer. Here we report the expression profile of the five SS receptor subtypes (hsst1-5) mRNAs in a large set of tumoral and normal colon. Using reverse transcription-PCR, we showed that hsst5, hsst1 and hsst2 mRNA subtypes were the most frequently expressed hsst mRNA subtypes in normal and pathological colon. Interestingly, we found that the frequency of hsst5 mRNA expression in the left colon was significantly higher in tumors than in normal samples: 81.2% (13/16) and 36.4% (4/11) respectively (0.025 > P > 0.01, x 2 test with Yates' correction). We did not find any influence of Dukes' stage on hsst mRNAs expression. Of interest, no loss of hsst2 and hsst5 mRNA expression in advanced stages was noted. Some differences in the frequency of expression of hsst mRNAs according to the origin of the tissue (left or right colon) were evident. The expression of hsst5 and hsst2 mRNA in advanced colorectal carcinoma associated with the development of new SS analogs boost the relevance of colorectal cancer treatment by somatostatin analogs.

show abstract

Inhibition of tumor cell kinetics and serum insulin growth factor I levels by octreotide in colorectal cancer patients

Cited by 28 publications

References 2 publications

The Effects of Insulin-Like Growth Factors on Tumorigenesis and Neoplastic Growth

The Effects of Insulin-Like Growth Factors on Tumorigenesis and Neoplastic Growth

Insulin-Like Growth Factor-I and Binding Protein-3 and Risk of Cancer

No loss of sst receptors gene expression in advanced stages of colorectal cancer

Contact Info

Product

Resources

About